Product Description
A Potent KRAS Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS. (Sourced from: https://www.benzinga.com/pressreleases/25/10/g48411056/cogent-biosciences-announces-kras-poster-presentation-at-the-2025-aacr-nci-eortc-international-con)
Mechanisms of Action: KRAS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Cogent Biosciences presented P0 Oncology Solid Tumor Unspecified results on 2025-10-24 for CGT-1263
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|